Jan 07 2022
The American Lung Association recently released its 2021 State of Lung Cancer report. Lung cancer is the leading cause of cancer deaths worldwide because the disease is often diagnosed at the late stages. Early diagnosis of lung nodules can help patients get treatment sooner and improve long-term survival rates. Auris is committed to fighting this deadly disease by helping physicians diagnose lung tumors in the early stages when they are small but difficult to reach. Using robotic technology, the MONARCH® Platform provides physicians with precision and continuous visualization to reach and diagnose nodules deep in the lung.Continue Reading
May 25 2020
AIS with collaboration with Johnson & Johnson Institute has launched a special website dedicated to internal and external content to help healthcare workers keep up on the latest news on COVID-19.Continue Reading
Apr 01 2020
COVID-19 has gripped this country and put unprecedented strain on our healthcare system. We are grateful for the incredible character and commitment displayed by the doctors, nurses, and staff on the front lines of this fight. Thank you health care workers who continue to put the health of others first and serve patients during this pandemic.Continue Reading
Oct 18 2019
Last night at the 26th Annual Phoenix Medical Device and Diagnostic Conference in Half Moon Bay, Calif., Auris Health recieved second place for the 2019 Phoenix Emerging Growth Company Award – a prestigious annual award that recognizes outstanding achievements by individuals and companies in the medical device and diagnostics industries.Continue Reading
Oct 11 2019
Auris™ Health celebrates being selected as the winner of Pharma Intelligence’s Medtech Insight Award in the category of Best Technological Innovation: Devices for its Monarch™ Platform, a first-of-its-kind robotic technology indicated for diagnostic and therapeutic bronchoscopic procedures.Continue Reading
May 14 2019
Auris was named in Robotics Business Review's RBR50 list for 2019 in the “Healthcare or Service Robots” category. This is the first year that Auris has been selected as part of the list.Continue Reading
Mar 27 2019
Auris Health celebrates being named the Red Dot: Best of the Best for product design. The award is an internationally sought-after recognition received by Auris for its Monarch Platform, a revolutionary flexible endoscopic platform featuring robotic technology that allows physicians to diagnose small, hard-to-reach peripheral nodules with greater precision than ever before.Continue Reading
Mar 01 2019
The Monarch Platform was featured on the cover of the March-April 2019 issue of Oncology Issues. The journal, which is the official journal of the Association of Community Cancer Centers, was created for multidisciplinary oncology teams to provide information on a range of topics in cancer care.Continue Reading
Feb 28 2019
Innovation begins when there is a need for something better. The Monarch™ Platform has been named a 2019 Edison Award finalist in the medical/dental category. The annual award competition honors excellence in new product and service development, marketing, human-centered design and innovation.Continue Reading
Bronchoscopy Important Safety Statement:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology Important Safety Statement:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.